RCS - Eden Research plc - Appointment of Global Commercial Lead

Eden ResearchAnnouncement

10/06/2024 09:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240610:nRSJ7843Ra&default-theme=true

RNS Number : 7843R  Eden Research plc  10 June 2024

10 June 2024

 

 

Eden Research Plc

("Eden" or "Company")

 

Appointment of Global Commercial Lead

Eden Research plc (AIM: EDEN), the AIM-quoted company focused on sustainable
biopesticides and plastic-free formulation technologies for use in the global
crop protection, animal health and consumer products industries, is delighted
to announce the appointment of Humair Tariq as the Company's new Global
Commercial Lead. Humair assumes his new role with immediate effect.

 

Humair has considerable experience in the crop protection industry, most
recently working for Syngenta as Portfolio Manager for biologicals, seed
treatment and insect control. Prior to that, he held a series of global and
regional positions with Syngenta in both Basel and Pakistan. Humair holds an
MBA degree with a focus on marketing.

 

Humair will be responsible for leading Eden's commercial efforts, fostering
the Company's existing partnerships, developing new relationships with
potential partners, and driving revenue growth through both the expansion of
our existing business and the pursuit of new opportunities.

 

Sean Smith, Chief Executive Officer of Eden Research, commented:

 

"We are pleased to welcome Humair Tariq to the Eden team as Global Commercial
Lead with immediate effect. Humair has spent the majority of his career
working within the food value chain and brings with him invaluable industry
experience and expertise. He joins a small but growing commercial team at
Eden, focused on growth and the creation of long-term value for our partners
and shareholders. Humair's appointment is a demonstration of our intent to add
to our team's resources and capabilities, supported by our stronger balance
sheet following last Summer's fundraise and our increasing revenue streams as
we continue to grow the company organically across various fronts. We look
forward to his contributions and the opportunities that lie ahead."

 

For further information contact:

 

 Eden Research plc
 Sean Smith                                                        www.edenresearch.com (http://www.edenresearch.com)

Alex Abrey

                                                                 01285 359 555

 Cavendish Capital Markets Limited (Nominated advisor and broker)
 Giles Balleny / George Lawson (corporate finance)                 020 7220 0500

Charlie Combe (corporate broking)

Michael Johnson (sales)

 Hawthorn Advisors (Financial PR)
 Victoria Ainsworth                                                eden@hawthornadvisors.com (mailto:eden@hawthornadvisors.com)

 

Notes to Editors:

 

Eden Research is the only UK-listed company focused on biopesticides for
sustainable agriculture. It develops and supplies innovative biopesticide
products and natural microencapsulation technologies to the global crop
protection, animal health and consumer products industries.

 

Eden's products are formulated with terpene active ingredients, based on
natural plant defence metabolites. To date, they have been primarily used on
high-value fruits and vegetables, improving crop yields and marketability,
with equal or better performance when compared with conventional pesticides.
Eden has three products currently on the market:

 

Based on plant-derived active ingredients, Mevalone® is a foliar
biofungicide which initially targets a key disease affecting grapes and other
high-value fruit and vegetable crops.  It is a useful tool in crop defence
programmes and is aligned with the requirements of integrated pest management
programmes. It is approved for sale in a number of key countries whilst Eden
and its partners pursue regulatory clearance in new territories thereby
growing Eden's addressable market globally.

 

Cedroz™( )is a bionematicide that targets free living nematodes which are
parasitic worms that affect a wide range of high-value fruit and vegetable
crops globally.  Cedroz is registered for sale on two continents and Eden's
commercial collaborator, Eastman Chemical, is pursuing registration and
commercialisation of this important new product in numerous countries
globally.

 

Eden's seed treatment product, Ecovelex was developed to safely tackle crop
destruction caused by birds - a major cause of losses in maize and other
crops. Ecovelex works by creating an unpleasant taste or odour that repels
birds, leaving the seeds safely intact and the birds unaffected and free to
find alternative food sources. The product is based on Eden's plant-derived
chemistry, registered in the EU, U.S. and elsewhere, and formulated using
Eden's Sustaine® microencapsulation system.

 

Eden's Sustaine(®)( )encapsulation technology is used to harness the
biocidal efficacy of naturally occurring chemicals produced by plants
(terpenes) and can also be used with both natural and synthetic compounds to
enhance their performance and ease-of-use. Sustaine microcapsules are
naturally-derived, plastic-free, biodegradable micro-spheres derived from
yeast. It is one of the only viable, proven and immediately registerable
solutions to the microplastics problem in formulations requiring
encapsulation.

 

Eden was admitted to trading on AIM on 11 May 2012 and trades under the
symbol EDEN. It was awarded the London Stock Exchange Green Economy
Mark in January 2021, which recognises London-listed companies that derive
over 50% of their total annual revenue from products and services that
contribute to the global green economy. Eden derives 100% of its total annual
revenues from sustainable products and services.

For more information about Eden, please visit:  www.edenresearch.com
(http://www.edenresearch.com/) .

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFIFEDRAIILIS